Tutorial reduces protocol deviations in multicenter ACTG trials with pharmacology endpoints

被引:6
作者
DiFrancesco, Robin
Rosenkranz, Susan L.
Craft, Jean
Morse, Gene D.
机构
[1] Univ Buffalo, Dept Pharm Practice, Buffalo, NY 14260 USA
[2] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Ctr Biostat AIDS Res, Boston, MA 02115 USA
[3] Indiana Univ Hosp, Infect Dis Res Clin, Indianapolis, IN 46202 USA
来源
HIV CLINICAL TRIALS | 2006年 / 7卷 / 04期
关键词
data accuracy; quality assurance; tutorial;
D O I
10.1310/hct0704-203
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: The AIDS Clinical Trials Group (ACTG) pharmacology quality assurance program requires clinical research staff to demonstrate minimum competencies in clinical pharmacology research. To achieve this goal, a tutorial was designed to improve the accuracy and completeness of data collected in ACTG pharmacology protocols. Method: Clinical research staff at AIDS Clinical Trials Units (ACTUs) access the tutorial through the network's Website. The tutorial presents pharmacokinetic study concepts by contrasting poor with perfect study conduct to illustrate the influence of data quality on conclusions. Case report forms and laboratory data were audited retrospectively to examine the pre- and posttutorial incidence of targeted errors. Results: During a 2-year period, 236 study nurses at 64 main and subunit ACTUs completed the tutorial. The percentage of visits with dosing and/or sampling errors dropped from 13% to 4%. The percentage of samples with errors decreased from 6% to 3%. Sample-time errors (blood drawn outside of the 15-minute target time) decreased slightly, from 2.9% to 2.4%, but the discrepancies found in the recording of sample times decreased from 3% to <1%. Conclusion: The ACTG clinical pharmacology tutorial program improved accuracy of both protocol conduct and data collection for pharmacology objectives.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 9 条
[1]   BINOMIAL CONFIDENCE-INTERVALS [J].
BLYTH, CR ;
STILL, HA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1983, 78 (381) :108-116
[2]  
*CYT INC, 2005, STATXACT 7 PROCS SAS
[3]   Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects [J].
DiCenzo, R ;
Forrest, A ;
Squires, KE ;
Hammer, SM ;
Fischl, MA ;
Wu, HL ;
Cha, R ;
Morse, GD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1929-1935
[4]  
DIFRANCESCO R, 2005, QUAL ASSUR J, V9, P23
[5]   Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 [J].
Fletcher, CV ;
Acosta, EP ;
Cheng, HL ;
Haubrich, R ;
Fischl, M ;
Raasch, R ;
Mills, C ;
Hu, XJ ;
Katzenstein, D ;
Remmel, RP ;
Gulick, RM .
AIDS, 2000, 14 (16) :2495-2501
[6]   Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group study 359 [J].
Fletcher, CV ;
Jiang, HY ;
Brundage, RC ;
Acosta, EP ;
Haubrich, R ;
Katzenstein, D ;
Gulick, RM .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (07) :1176-1184
[7]  
Haas DW, 2004, AIDS, V18, P2391
[8]  
JIANGFENG L, 2002, DRUG METAB DISPOS, V30, P1455
[9]   Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study [J].
Ribaudo, HJ ;
Haas, DW ;
Tierney, C ;
Kim, RB ;
Wilkinson, GR ;
Gulick, RM ;
Clifford, DB ;
Marzolini, C ;
Fletcher, CV ;
Tashima, KT ;
Kuritzkes, DR ;
Acosta, EP .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) :401-407